Visão geral da empresa
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company focused on the development of off-the-shelf, precision T cell therapies designed for the treatment of infectious diseases, cancers, and various other disorders. The enterprise functions within the Healthcare sector, specifically targeting the Biotechnology industry, where it seeks to advance therapeutic solutions that address significant unmet medical needs through innovative cellular engineering. The company maintains a lean operational structure with a workforce comprising 18 employees and holds a market capitalization of $24.19 million. These valuation and revenue figures indicate that Tevogen Bio is a micro-cap entity operating with limited current commercial scale, relying heavily on future clinical milestones to transition from a research phase toward commercial viability rather than generating substantial annual revenue at this stage.
Saúde financeira
The financial performance of Tevogen Bio Holdings Inc. reflects the typical characteristics of a pre-commercial biotechnology firm, reporting a Net Income (TTM) of $-26,825,432 and an EBITDA of $-25,949,942 against a revenue figure that is currently unavailable. The substantial gap between the negligible revenue and the deep net loss reveals a cost structure dominated by research and development expenditures and operational overheads required to advance the company's pipeline, specifically the development of TVGN 489 for the treatment of ambulatory disease conditions. The company generated Free Cash Flow of $-1,774,858 during the trailing twelve months, which indicates a reliance on external capital markets or existing cash reserves to fund operations rather than self-sustaining cash generation. Margins across the board show zero profitability, with a Gross Margin of 0.0%, an Operating Margin of 0.0%, and a Profit Margin of 0.0%, reflecting the high-risk nature of clinical-stage development where revenues have not yet materialized to cover costs. Liquidity analysis shows the company holds $552,372 in cash while carrying $7.50M in debt, resulting in a current ratio of 0.22, which signals potential short-term liquidity constraints as current liabilities significantly exceed current assets. The balance sheet is highly leveraged, evidenced by the debt load relative to minimal cash, and return metrics are distorted by the lack of equity value, showing a Return on Assets of -416.5% and a Return on Equity that is not applicable due to the negative equity position.
Avaliação de valorização
Valuation metrics for Tevogen Bio Holdings Inc. present a challenging picture due to the absence of traditional earnings-based multiples, as both the P/E Ratio (TTM) and Forward P/E are listed as N/A. The lack of a positive earnings base renders the P/E comparison meaningless and implies that investors cannot value the stock based on historical or future expected earnings per share. Instead, the Price to Book ratio stands at -2.74, a negative figure that indicates the market is pricing the company below its net asset book value, often seen in distressed or highly speculative biotech situations where asset liquidation value differs significantly from enterprise value. Alternative valuation multiples such as the Price to Sales ratio, which is N/A, and the EV/EBITDA of -1.54, further underscore the inability to use standard profitability metrics for valuation, suggesting the price is disconnected from current sales performance. Historical price data shows a 52-Week High of $75.50 and a 52-Week Low of $4.13, meaning the stock price has experienced extreme volatility within this range over the past year. The Beta value of -0.30 is anomalous for equities, suggesting the stock's price movements have historically moved inversely or with negligible correlation to the broader market index, which is highly unusual and warrants caution in risk assessment models.
Growth & Income
Growth metrics for the company are currently unavailable, with Revenue Growth (YoY) and Earnings Growth (YoY) both listed as N/A, which prevents any meaningful comparison between the expansion of sales and the improvement in profitability. Since the company has not yet generated commercial revenue to support dividend payments, the Dividend Yield is N/A and the Payout Ratio is 0.0%, indicating that no cash is distributed to shareholders. Consequently, the company reinvests all available financial resources, however limited, back into its research and development efforts rather than paying dividends to income-focused investors. The overall growth and income profile is defined entirely by clinical progression and capital raising activities, as there is no current earnings growth to sustain a dividend policy or to indicate a trajectory of rapid revenue expansion.